ClinicalTrials.gg
Status unknownNCT03675841Updated Sep 26, 2018

Pazufloxacin Mesilate Ear Drops in Patients With Chronic Suppurative Otitis Media

A Phase 1 interventional study of Pazufloxacin Mesilate ear drops in Chronic Suppurative Otitis Media, sponsored by Lee's Pharmaceutical Limited. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-26.

Sponsored by Lee's Pharmaceutical Limited · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Objective To observe the safety and tolerability of Pazufloxacin Mesylate Ear Drops of different concentrations in patients with simple chronic suppurative otitis media.

Read the detailed description

The test group was completed in sequence from low to high concentrations, and safety tolerance was assessed after administration in one concentration group to determine whether to conduct follow-up group studies and, if necessary, adjust sampling time points according to pre-experimental results.

02

Conditions studied

  • Chronic Suppurative Otitis Media

Browse trials for

Keywords

  • Pazufloxacin Mesilate ear drops
03

In context

Otitis Media

241 studies on the registry are indexed under Otitis Media; 32 are open to participants now.

This study's planned enrollment of 33 is below the median of 165 across 174 interventional studies indexed under Otitis Media.

Browse Otitis Media studies →

Lead sponsor

Lee's Pharmaceutical Limited is the lead sponsor of 74 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age is 18-65 years old. Men and women are not restricted.
  2. Clinical diagnosis of simple chronic suppurative otitis media with ear effusion secretion, tympanic membrane perforation about 2 mm, the need for local use of antibiotics in patients.
  3. Voluntarily sign written .
  4. Non-breast-feeding women volunteered to take appropriate measures (including abstinence, intrauterine devices, diaphragms and spermicides) during the study period (screening period to one week after administration). Men are willing to use approved contraceptive methods (including the use of condoms and spermicides or the use of oral, implantable or injectable contraceptives by their partners, intrauterine devices, diaphragms and spermicides) or sexual partner infertility.

Exclusion criteria

Exclusion Criteria:

  1. Quinolone antibiotics allergy and severe allergic constitution.
  2. During the study, ear fluid could not be collected.
  3. Patients with severe need for systemic use of antibiotics.
  4. Infections caused by pathogens such as fungi and viruses (bullous tympanitis).
  5. Patients with cholesteatoma.
  6. Complicated with symptoms of extraaural infection (such as periaural cellulitis, mumps) or intracranial and extracranial complications (such as meningitis, brain abscess, thrombophlebitis of sigmoid sinus, subperiosteal abscess of the ear, Bezold's abscess of the neck).
  7. Suffer from severe brain, heart, lung, liver, kidney and blood diseases.
  8. People suffering from severe diseases that affect their survival, such as malignant tumors or AIDS, etc.
  9. Abnormal liver and kidney function (, Angiotensin sensitivity test(AST) ≥ 1.5 times the value), rate \< 60ml/min).
  10. Use any local or systemic antibiotics in the first 3 days of the admission.
  11. Use any quinolones within the first 7 days of admission.
  12. There were smokers who smoked more than 5 cigarettes a day within one year.
  13. There was a history of alcoholism and drug abuse within one year.
  14. Diagnosis of diabetes or poor blood glucose control.
  15. Those who are unable to cooperate or unwilling to cooperate with neuropsychiatric disorders.
  16. Pregnant or lactating women, those who do not use measures as required, or those who are unwilling to take contraceptive measures.
  17. Patients who took part in other clinical trials in the first 3 months.
  18. Blood donation within three months before admission, or intended during or three months after the end of the trial or blood components.
  19. Researchers believe that patients who are not fit to participate in this clinical trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    0.1% single-dose pre

    Three subjects will be treated with Pazufloxacin Mesilate ear drops 0.1% single dose

    Drug: Pazufloxacin Mesilate ear drops

  • Experimental
    0.1% single-dose

    Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.1% single dose

    Drug: Pazufloxacin Mesilate ear drops

  • Experimental
    0.3% single-dose

    Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.3% single dose

    Drug: Pazufloxacin Mesilate ear drops

  • Experimental
    0.5% single-dose

    Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.5% single dose

    Drug: Pazufloxacin Mesilate ear drops

Interventions

  • DrugPazufloxacin Mesilate ear drops

    Pazufloxacin Mesilate ear drops of 0.1%,0.3%,0.5%

    Also known as: ear drops

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Objective To observe the safety and tolerability of Pazufloxacin Mesylate Ear Drops of different concentrations in patients with simple chronic suppurative otitis media.

    Time frame: Within two days after administration

Secondary outcomes

  1. Cmax

    Pharmacokinetics

    Time frame: Within two days after administration

  2. Tmax

    Pharmacokinetics

    Time frame: Within two days after administration

  3. Area under concentration time curve

    Pharmacokinetics

    Time frame: Within two days after administration

07

Study locations

1 of 1 sites recruiting
  • Jiangsu Province People's Hospital
    Nanjing, Jiangsu 210029, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2018 (actual). Primary completion is estimated for Jan 2019, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2018
First posted
Sep 18, 2018
StartActual
Jul 29, 2018
Primary completionEst.
Jan 30, 2019
CompletionEst.
Jun 28, 2019
Last update
Sep 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03675841
Responsible party
Sponsor
First posted
Sep 18, 2018
Start date
Jul 29, 2018
Primary completion
Jan 30, 2019 (estimated)
Completion
Jun 28, 2019 (estimated)
Last update
Sep 26, 2018

Study contacts

lei chen, PHD
Contact
jspent@126.com
13776620807
fen shao, PHD
Contact
shaofengnj@163.com
13851691161
lei chen, PHD
study director · Jiangsu Province People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion